Research Paper Volume 16, Issue 4 pp 3160—3184
Single-cell and bulk RNA sequencing data jointly reveals VDAC2’s impacts on prognosis and immune landscape of NSCLC
Figure 7. NSCLC patients with distinct VDAC2 expression exhibited different clinical responses. (A) The waterfall plot of somatic mutation. (B, C) The level of TMB in high and low VDAC2 expression groups. (D, E) The expression of immune checkpoints in high and low VDAC2 expression groups. * p <0.05, ** p<0.01; *** p<0.001.